24-week data from the clinical trial showed at least a 20% improvement in disease signs and symptoms compared to placebo. More: Tremfya hits endpoints in psoriatic arthritis study Source: News
read moreThe committee accepted breast cancer and kidney cancer treatments, but rejected one non-small cell lung cancer (NSCLC) therapy. More: Kisqali leads latest SMC decisions Source: News
read moreThe drug met its primary endpoint, demonstrating superiority compared to placebo with standard of care. More: Roche's Gazyva shows promise in lupus nephritis Source: News
read moreThis year’s event will be taking place at The Hilton Hotel in Reading on the 5th December. More: Tickets now available for the 2019 Medical & Scientific Excellence Awards ceremony Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals